 RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2021 GLOBE NEWSWIRE -- BioCryst Pharmaceuticals, Inc. Nasdaq: BCRX today announced that the new drug submission for ORLADEYO berotralstat has been accepted for review by Health Canada for the prevention of recurrent attacks in patients with hereditary angioedema HAE 12 years and older. The company also announced that Swissmedic has accepted BioCrysts marketing authorization application for ORLADEYO for review. 